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Stent Speciﬁc Temporal Pattern of Coverage and Malapposition as Detected
by OCT
Stent <1m 1m 2m 3-5m 6-8m 9-11m 12-15m 16-20m 21-30m 31-40m 41-50m
51-
60m
BMS
(%)
Unc 13.7 3.5 0.1 0.5 0.7 1.1 1.2 0.3
Mal 12.1 1.2 1.1 0.1 0.1 0.0 0.0
PES (%) Unc 4.9 4.8 4.8 6.5 3.1 10.8 1.0
Mal 2.5 1.8 1.3 1.0 13.8 0.7
SES (%) Unc 15.0 13.4 10.1 10.3 10.5 5.0 4.1 1.8 1.5
Mal 15.5 3.0 2.8 3.6 3.0 4.3 0.3 3.9 1.2
ZES-E
(%)
Unc 90.6 37.3 10.8 0.4 0.4 1.7 3.0 0.2 0.1
Mal 0.9 0.3 0.2 0.1 0.2 0.1 1.7 0.2
ZES-R
(%)
Unc 6.2 7.4 7.4
Mal 0.7 1.5 1.8
EES Unc 62.5 52.6 21.5 3.6 4.9 2.2 0.4
Mal 0.5 1.0 0.8 1.0 1.3 0.6 0.1
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Impact on Mortality of Non-Infarct Related Artery Coronary Chronic Total
Occlusion in Patients Presenting With ST-Segment Elevation Myocardial
Infarction: A Systematic Review and Meta-Analysis
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Background: To evaluate the impact of the presence of a chronic total occlusion
(CTO) on short and long term mortality after primary percutaneous coronary inter-
vention (PPCI).
Methods: We performed MEDLINE, Cochrane Controlled Trials Registry and
EMBASE database searches for published articles using predeﬁned terms. Studies that
reported data on the incidence of all-cause mortality in STEMI patients with single- or
multivessel disease (SVD, MVD) with and without CTO were included. Of the 189
studies identiﬁed, 5 articles met the inclusion criteria: 3 observational studies and 2
post-hoc analyses of randomized controlled trials (RCTs).
Results: A total of 10,314 patients were included in the meta-analysis with overall
1160 (11%) patients with CTO. The global analysis demonstrated that CTO was
associated with an over 3-fold increased incidence of mortality at a median follow up
of 36 months compared to patients non-CTO patients (30.4% vs 10.1% OR: 3.24; 95%
conﬁdence interval [CI]: 2.79 to 3.75; p 0.0001) (Figure). This ﬁnding was consistent
in a sub-analysis of studies that reported 30-day follow up (17.6% vs 4.2 OR: 4.3;
95% CI: 3.4 to 5.4 p¼0.001). Cardiac mortality and MACE were also higher in
patients with CTO (14.7% vs 3.7% OR: 4.42; 95% conﬁdence interval [CI]: 3.18 to
6.15; p <0.0001 and 33.5% vs 20.4% OR: 1.97; 95% conﬁdence interval [CI]: 1.56 to
2.47; p <0.0001 respectively).
Conclusions: Coronary chronic total occlusion in the non-culprit artery in patients
presenting with STEMI is associated with poor long-term mortality.TCT-849
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Background: Statin loading prior to percutaneous coronary intervention (PCI) has
been shown to decrease peri-procedural myocardial infarction but less is known
regarding the clinical beneﬁt of pre-procedural statin loading. We aimed to investigate
this hypothesis in stable patients and among patients with Non ST elevation acute
coronary syndromes(NSTE-ACS).B256 JACC Vol 62/18/Suppl B j October 27–NoMethods: We performed a PubMed and Scopus databases search from 1966 through
March 2013 of trials of stable patients and patients with NSTE-ACS treated with high
dose statins prior to PCI. We evaluated the incidence of major cardiac events including
death, spontaneous MI, target vessel revascularization and stent thrombosis. We used
ﬁxed effect analysis when the I2 was up to 40% and the P at least 0.10, otherwise we
used random effect.
Results: Out of 1188 articles, 15 randomized controlled trials were included in this
meta-analysis. Among 3529 patients, 1783 patients were randomized to a loading dose
of statin pre PCI and 1746 patients were given statin therapy initiated only after the
PCI. There was a 43% reduction in clinical events in followup in the group of patients
treated with pre-procedural statin loading, (OR: 0.57, 95%, 0.37-0.89, p¼0.01) When
stratiﬁed according to clinical presentation, this result was only signiﬁcant for those
patients with NSTE-ACS, (OR: 0.18, 95% CI 0.07-0.47, p¼0.0005) (ﬁgure) and was
not noted in the group of patients who underwent PCI for stable angina (OR: 1.0, 95%
CI 0.58-1.72, p¼NS)
Conclusions: Pre-treatment with high dose statins prior to PCI in patients with NSTE-
ACS is associated with a major reduction in clinical events.TCT-850
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Methods: An unadjusted random-effects meta-analysis was performed in 3 random-
ized and 14 observational studies involving 26,503 patients.
Results: IVUS-guided PCI was signiﬁcantly associated with a longer and bigger
stent implantation and a larger post procedure angiographic minimum lumen
diameter (MLD). The mean difference was 0.18 mm (95% conﬁdence interval [CI]
0.06 to 0.29, P¼0.003), 0.29 mm (95% CI 0.20 to 0.39, P<0.001), 0.33 mm (95%
CI 0.25 to 0.50, P<0.001) for stent length, stent diameter, and MLD, respectively.
Regarding the clinical outcomes, IVUS-guided PCI was associated with a signiﬁ-
cantly lower risk of major adverse cardiac events (MACE) (odds ratio [OR] 0.79,
95% CI 0.67 to 0.94, P¼0.007), death (OR 0.65, 95% CI 0.52 to 0.82, P<0.001),
myocardial infarction (OR 0.55, 95% CI 0.40 to 0.74, P<0.001), repeat revascu-
larization (OR 0.84, 95% CI 0.71 to 0.99, P¼0.04), and stent thrombosis (OR 0.59,
95% CI 0.45 to 0.78, P<0.001).
Conclusions: IVUS-guided PCI was associated with lower risks of adverse clinical
outcomes including the reduction of MACE, death, myocardial infarction, repeat
revascularization, and stent thrombosis. This meta-analysis may encourage the use of
IVUS for PCI in patients undergoing DES implantation.
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Background: To perform a systematic review and meta-analysis of studies reporting
outcomes after ﬁrst- and second- generation drug-eluting stent (DES) implantation in
chronic total occlusions (CTOs).
Methods: As of May 2013, 31 published studies reported outcomes after DES
implantation in CTOs: 13 uncontrolled studies (3161 patients), 3 randomized (220
patients) and 10 non-randomized (2150 patients) comparative studies with bare-metal
stents (BMS), and 2 non-randomized (685 patients) and 3 randomized (489 patients)
comparative studies between ﬁrst and second generation DES. Data were pooled using
random-effects meta-analysis models.vember 1, 2013 j TCT Abstracts/POSTER/Meta-Analyses and Reviews
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMResults: Mean follow-up period was 14.4 months. Compared to ﬁrst generation DES,
second generation DES were associated with lower incidence of death, myocardial
infarction, and target vessel revascularization (TVR), binary angiographic restenosis
and re-occlusion (Table 1).2ndgeneration DES
(n/N)
2ndgeneration DES
event rate (%)
1stgeneration DES
(n/N)
1
Death 7/588 1.2 20/586
Myocardial
infarction
5/588 0.8 14/586
TLR 11/214 5.1 18/212
TVR 49/542 9 77/535
MACE 66/588 11.2 109/586
Stent thrombosis 2/588 0.3 7/586
Binary restenosis 48/469 10.2 67/464
Reocclusion 11/398 2.8 30/391
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Compared to ﬁrst-generation DES, second generation stents are asso-
ciated with less angiographic and clinical restenosis, making them the preferred
therapy for percutaneous revascularization of CTOs.st generation DES
event rate (%) Odds ratio 95% CI I2
3.4 0.35 0.15 - 0.82 0%
2.4 0.38 0.14 - 1.03 36%
8.5 0.59 0.27 - 1.28 0%
14.4 0.59 0.40 - 0.87 0%
18.6 0.55 0.40 – 0.77 0%
1.2 0.43 0.13 - 1.41 18%
14.4 0.58 0.46 – 1.01 0%
7.7 0.34 0.17 – 0.69 0%
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